Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information has been received from Sanofi Pasteur MSD (SPM) (DK-1577272925-2016007283) on 13-JUL-2016. NOTE TO AGENCY: Please do not return cases received from the Medicines Agency (MA) unless you received new information regarding this case. Please remember to use the Worldwide unique case identification number for this case: DK-DKMA-WBS-0003982. Also, please note that information should not be deleted from the case (especially not the Patient characteristics). Case received from a physician via HA on 11-Jul-2016, under the reference number DK-SKMA-WBS-0003982. A 13-year-old female adolescent patient received GARDASIL (batch number Lot unknown, Dose 1) via intramuscular route on 21-Jan-2009, GARDASIL (batch number Lot unknown, dose 2) via intramuscular route on 31-Mar-2009, GARDASIL (batch number Lot unknown, dose 3) via intramuscular route on 11-Aug-2009. The patient experienced Migraine aura (JUL-2009), Light sensitive (2009), memory problems (2011), concentration problems (2015), dizziness (2009), shortness of breath mainly while resting (2012), radiating pain in arm (2014), drops things from hands which suddenly loose grip (2014), diarrhoea periodically notable with general symptoms (JUL-2009 and outcome : recovering/resolving). Nausea (2010), tiredness (2009), mood swings (2011), dry mouth (2013), high degree of absence from education and difficulties completing it (unknown date), burning behind the sternum (2010), fragmentary sleep during the last year (2009) and beginning periodontosis (2013). The patient had a medical history of asthma exercise induced. No other medications or vaccines. The patient''s outcome was reported as Not Recovered/Not resolved.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166